HCW Biologics Inc (HCWB): HCWB: Whelp, unfortunately --- not to tr...

HCWB: Whelp, unfortunately --- not to trivialize

Invest-in-America · 2024-11-18T20:08:43.3700000Z

HCWB: Whelp, unfortunately --- not to trivialize its magnificent RUN-UP earlier today --- here's its latest ' CHART ', Peeps!! (See below.) https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExcmJoY2dqeGxqM3VhN3Bzd2oxdDFndTgzYzRkZWNhbmk4cTlrbmFkaiZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/sZNcvnnSSfWrC/giphy.gif

Play Episode

3min

Proactive - Interviews for investors

Nevis Brands doubles revenue in 2024, cuts losses & expands in key Markets

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to discuss the company’s financial results for fiscal year 2024 and the fourth quarter ending November 30, 2024. Nevis reported $1.56 million in revenue, more than doubling its 2023 sales as it expanded into new markets and introduced new cannabis products. The company narrowed its net loss to approximately $362,000, down from $400,000 the previous year. When excluding interest, depreciation, and amortization, the adjusted loss was reduced to about $58,000. Nevis maintained its leading position in Washington’s cannabis beverage market and achieved the second-best sales ranking in Missouri within its first year in that state. The company also made significant progress in debt reduction, cutting current liabilities from $1.12 million to about $573,000 through debt payments and restructuring. Looking ahead to 2025, Nevis expects continued growth driven by expanding sales of its Happy Apple and Major brands in the hemp-derived THC beverage market. The company also looking for market re-entry in Ohio and Arizona following previous licensing and market shifts. All this happening while the company focused on licensing established products in key markets. Kueber acknowledged that the fourth quarter was challenging, with revenue declines due to licensing and market shifts in Arizona, Ohio, Oregon, and California. However, growth in New Jersey and Missouri helped offset these declines, and the company remains focused on long-term expansion and profitability. #proactiveinvestors #nevisbrandsinc #cse #nevi #otcqb #nevif #majorbrand #cannabis #CannabisInvesting #THCDrinks #HappyApple #CannabisStocks #HempTHC #CannabisBeverages #InvestorUpdate #JohnKueber #CannabisNews #CannabisRevenue #DebtReduction #ProactiveInvestors

Proactive - Interviews for investors

BioHarvest Sciences reports record-breaking 2024 revenue and expansion milestones

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to discuss the company’s impressive financial and operational performance for the fourth quarter and full year ended December 31, 2024. The company reported a remarkable 62% increase in fourth-quarter revenues, reaching $7.3 million, while full-year revenue surged by 99% year-over-year to $25.2 million, surpassing prior guidance. A key driver of this growth has been the continued expansion of VINIA®, BioHarvest’s flagship product line. As of February 2025, total VINIA® subscribers exceeded 50,000, contributing to a cumulative revenue milestone of $50 million since launch. Building on this momentum, the company successfully introduced its VINIA SuperFood Tea line, leveraging its "VINIA Inside" strategy following the successful launch of VINIA SuperFood Coffee in December 2023. Beyond its financial success, BioHarvest achieved several strategic milestones in 2024. Sobel highlighted a groundbreaking partnership with Tate & Lyle to develop plant-based sweeteners, further validating BioHarvest’s innovative Botanical Synthesis platform. Additionally, the company expanded its VINIA product portfolio and completed a successful uplisting to the Nasdaq Global Market, strengthening its position for accelerated growth and operational efficiency in 2025. With a strong foundation and continued product innovation, BioHarvest Sciences is poised to drive further market expansion and deliver sustained shareholder value in the coming year. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

Hillcrest launches ZVS technology evaluation with global Tier 1 automotive supplier

Hillcrest Energy Technologies CEO Don Currie joined Steve Darling from Proactive to announce the launch of a technology evaluation project with a global Tier 1 automotive supplier. The project’s initial phase will assess the potential benefits of Hillcrest’s Zero Voltage Switching (ZVS) technology in next-generation inverter applications for electric vehicles. If this phase is successful and both parties agree to proceed, subsequent phases will focus on the integration and validation of ZVS technology within the supplier’s inverter platform. Currie explained that Tier 1 automotive suppliers provide fully assembled components and systems to major automakers. This particular supplier, consistently ranked among the top 15 largest by revenue, is a global leader specializing in critical EV components like inverters. With a strong presence in the industry, the supplier plays a crucial role in advancing electric vehicle technology for manufacturers worldwide. The evaluation phase will involve a series of technical assessments aimed at eliminating switching losses and improving electromagnetic compatibility (EMC) performance. The supplier will analyze efficiency, performance, and potential advantages of Hillcrest’s ZVS technology within its inverter architecture. The findings from this evaluation will determine potential next steps for further collaboration and integration. This project represents a key opportunity for Hillcrest to demonstrate the value of its ZVS technology, with the shared objective of enhancing EV inverter performance and delivering significant benefits to automotive customers. #proactiveinvestors #hillcrestenergytechnologiesltd #cse #heat #ptcqb #hlrtf

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Followers	220
Posts	13482
Boards Moderated	3
Alias Born	06/20/2022

Volume:	197,626
Day Range:	0.2178 - 0.245
Bid:	0.2227
Ask:	0.23
Last Trade Time:	7:59:04 PM EDT
Total Trades:	2,856

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

HCWB Detailed Quote

Recent HCWB News

More HCWB News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent HCWB News

Go Ad-Free